A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2013
At a glance
- Drugs Pazopanib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.